GSK (LON:GSK) Earns “Buy” Rating from Shore Capital

GSK (LON:GSK)‘s stock had its “buy” rating restated by equities research analysts at Shore Capital in a report issued on Friday, MarketBeat reports. They presently have a GBX 2,000 ($26.85) target price on the stock. Shore Capital’s price objective would indicate a potential upside of 48.37% from the company’s current price.

A number of other analysts have also commented on GSK. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a research note on Friday. Berenberg Bank reissued a “hold” rating and set a GBX 1,600 ($21.48) price objective on shares of GSK in a research report on Friday. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a GBX 1,450 ($19.46) price objective on shares of GSK in a research report on Tuesday, July 8th.

GSK Stock Down 4.6%

Shares of LON GSK opened at GBX 1,348 ($18.09) on Friday. GSK has a one year low of GBX 1,242.50 ($16.68) and a one year high of GBX 1,678.68 ($22.53). The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73. The firm’s 50 day simple moving average is GBX 1,435.32 and its two-hundred day simple moving average is GBX 1,422.65. The stock has a market capitalization of £54.70 billion, a P/E ratio of 21.78, a PEG ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last issued its earnings results on Wednesday, April 30th. The company reported GBX 44.90 ($0.60) earnings per share (EPS) for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. As a group, analysts expect that GSK will post 175.980975 EPS for the current fiscal year.

Insider Buying and Selling at GSK

In related news, insider Wendy Becker acquired 545 shares of the stock in a transaction dated Friday, June 20th. The shares were purchased at an average cost of GBX 1,435 ($19.26) per share, with a total value of £7,820.75 ($10,497.65). Also, insider Emma Walmsley sold 5,473 shares of GSK stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of GBX 1,449 ($19.45), for a total value of £79,303.77 ($106,448.01). Insiders bought a total of 1,905 shares of company stock worth $2,732,835 in the last three months. 1.61% of the stock is currently owned by company insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.